Gofar Stock(SH:600538) Zhong Zheng Wang·2025-08-27 14:56Group 1 - The chairman of Guofa Co., Ltd., Jiang Ye, has completed a share buyback plan, acquiring a total of 4.8049 million shares for approximately 30.0166 million yuan [1] - Jiang Ye's recent share purchases occurred on multiple dates, with the total amounts being 9.888 million yuan, 4.1022 million yuan, 11.9964 million yuan, and 2.0304 million yuan for shares acquired on August 19, 20, 21, and 24 respectively [1] - Another executive, Wu Peicheng, also completed a share buyback plan, acquiring 381,500 shares for approximately 2.1393 million yuan, holding 0.74% of the company's total shares post-purchase [1] Group 2 - Guofa Co., Ltd. operates in pharmaceutical manufacturing and distribution, judicial in vitro diagnostics (IVD), and molecular medical imaging centers, generating 15.4 million yuan in revenue in the first half of 2025, with a net loss of 5.8417 million yuan, a 63.74% year-on-year reduction [2] - The pharmaceutical manufacturing segment includes products like "Haibao" pearl eye drops, contributing 1.274 million yuan in revenue, while the pharmaceutical distribution business generated 9.537 million yuan from operations in the Beibu Gulf region [2] - The IVD and molecular medical imaging center business, primarily through subsidiaries, achieved 4.362 million yuan in revenue in the first half of 2025 [2] Group 3 - Guofa Co., Ltd. is undergoing a strategic transformation and has made significant personnel adjustments to enhance its governance structure, appointing Zhang Xiaowei as president and Li Feng as assistant president [3] - The company plans to accelerate business innovation through a private placement financing and has engaged an auditing firm for this issuance [3] - Guofa Co., Ltd. is exploring opportunities in the AI sector, signaling potential strategic investments in "AI + health" and AI computing power, following a visit to a leading cloud-native technology company [3]